Therapeutic targeting of Myc-reprogrammed cancer cell metabolism
- PMID: 21960526
- DOI: 10.1101/sqb.2011.76.011296
Therapeutic targeting of Myc-reprogrammed cancer cell metabolism
Abstract
Studies from many laboratories document that the MYC oncogene produces a pleiotropic transcription factor, Myc, which influences genes driven by all three RNA polymerases to orchestrate nutrient import with biomass accumulation for cell division. Myc has been shown to activate genes involved in glycolysis, glutaminolysis, and mitochondrial biogenesis to provide ATP and anabolic substrates for cell mass accumulation. Myc stimulates ribosome biogenesis and orchestrates the energetic demand for biomass accumulation through its regulation of glucose and glutamine import and metabolism. When normal cells are deprived of nutrients, endogenous MYC expression diminishes and cells withdraw from the cell cycle. However, ectopic MYC-driven cancer cells are locked in a state of deregulated biomass accumulation, which renders them addicted to glucose and glutamine. This addictive state can be exploited for cancer therapy, because nutrient deprivation kills Myc-driven cells and inhibition of the Myc targets, lactate dehydrogenase A or glutaminase, diminishes tumor xenograft growth in vivo.
Similar articles
-
Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.Oncotarget. 2015 Sep 22;6(28):26161-76. doi: 10.18632/oncotarget.4544. Oncotarget. 2015. PMID: 26317652 Free PMC article.
-
A Time for MYC: Metabolism and Therapy.Cold Spring Harb Symp Quant Biol. 2016;81:79-83. doi: 10.1101/sqb.2016.81.031153. Epub 2017 Feb 7. Cold Spring Harb Symp Quant Biol. 2016. PMID: 28174256 Review.
-
MYC-induced cancer cell energy metabolism and therapeutic opportunities.Clin Cancer Res. 2009 Nov 1;15(21):6479-83. doi: 10.1158/1078-0432.CCR-09-0889. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861459 Free PMC article. Review.
-
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.Mol Cancer. 2006 Aug 9;5:31. doi: 10.1186/1476-4598-5-31. Mol Cancer. 2006. PMID: 16899113 Free PMC article.
-
Impact of MYC in regulation of tumor cell metabolism.Biochim Biophys Acta. 2015 May;1849(5):563-9. doi: 10.1016/j.bbagrm.2014.07.004. Epub 2014 Jul 17. Biochim Biophys Acta. 2015. PMID: 25038584 Review.
Cited by
-
Cancer cell metabolism: one hallmark, many faces.Cancer Discov. 2012 Oct;2(10):881-98. doi: 10.1158/2159-8290.CD-12-0345. Epub 2012 Sep 25. Cancer Discov. 2012. PMID: 23009760 Free PMC article. Review.
-
Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.Clin Cancer Res. 2015 Jul 15;21(14):3263-73. doi: 10.1158/1078-0432.CCR-14-1200. Epub 2015 Mar 26. Clin Cancer Res. 2015. PMID: 25813021 Free PMC article.
-
MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.Mol Cancer. 2014 Oct 23;13:239. doi: 10.1186/1476-4598-13-239. Mol Cancer. 2014. PMID: 25339305 Free PMC article.
-
The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.EMBO J. 2017 Jul 3;36(13):1854-1868. doi: 10.15252/embj.201796662. Epub 2017 Apr 13. EMBO J. 2017. PMID: 28408437 Free PMC article.
-
Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.Cancer Cell. 2015 Feb 9;27(2):271-85. doi: 10.1016/j.ccell.2014.11.024. Epub 2015 Jan 29. Cancer Cell. 2015. PMID: 25640402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources